文章：

脂质运载蛋白-2：肿瘤进展的滋养因子与靶向癌症治疗的新候选靶点

Lipocalin-2: A Nurturer of Tumor Progression and a Novel Candidate for Targeted Cancer Therapy

原文发布日期：26 October 2023

DOI: 10.3390/cancers15215159

类型: Article

开放获取: 是

英文摘要：

Within the tumor microenvironment (TME) exists a complex signaling network between cancer cells and stromal cells, which determines the fate of tumor progression. Hence, interfering with this signaling network forms the basis for cancer therapy. Yet, many types of cancer, in particular, solid tumors, are refractory to the currently used treatments, so there is an urgent need for novel molecular targets that could improve current anti-cancer therapeutic strategies. Lipocalin-2 (Lcn-2), a secreted siderophore-binding glycoprotein that regulates iron homeostasis, is highly upregulated in various cancer types. Due to its pleiotropic role in the crosstalk between cancer cells and stromal cells, favoring tumor progression, it could be considered as a novel biomarker for prognostic and therapeutic purposes. However, the exact signaling route by which Lcn-2 promotes tumorigenesis remains unknown, and Lcn-2-targeting moieties are largely uninvestigated. This review will (i) provide an overview on the role of Lcn-2 in orchestrating the TME at the level of iron homeostasis, macrophage polarization, extracellular matrix remodeling, and cell migration and survival, and (ii) discuss the potential of Lcn-2 as a promising novel drug target that should be pursued in future translational research.

摘要翻译： 

在肿瘤微环境（TME）中，癌细胞与基质细胞之间存在着复杂的信号网络，这一网络决定了肿瘤进展的命运。因此，干扰这一信号网络构成了癌症治疗的基础。然而，许多类型的癌症，特别是实体瘤，对当前使用的治疗方法具有抵抗性，因此迫切需要能够改进现有抗癌治疗策略的新型分子靶点。脂质运载蛋白-2（Lcn-2）是一种分泌型铁载体结合糖蛋白，可调节铁稳态，在多种癌症类型中高度上调。由于其在癌细胞与基质细胞之间的串扰中具有多效性作用，并促进肿瘤进展，因此可被视为预后和治疗的新型生物标志物。然而，Lcn-2促进肿瘤发生的具体信号通路仍不明确，且针对Lcn-2的靶向分子在很大程度上尚未得到研究。本综述将（i）概述Lcn-2在铁稳态、巨噬细胞极化、细胞外基质重塑以及细胞迁移和存活等方面协调肿瘤微环境的作用，并（ii）探讨Lcn-2作为一种有前景的新型药物靶点的潜力，值得在未来的转化研究中进一步探索。

原文链接：

Lipocalin-2: A Nurturer of Tumor Progression and a Novel Candidate for Targeted Cancer Therapy